2.Y. Wu, J. Zhao, J. Hu,etc.388P - Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study[J].ESMO Asia Congress 2022.3. 牛娜.非小细胞肺癌 ＭＥＴ基因...
EXON 14 SKIPPING MUTATION 首页/癌基因/MET/ EXON 14 SKIPPING MUTATION MET基因编码的蛋白为肝细胞生长因子受体HGFR,具有酪氨酸激酶活性,与多种癌基因产物和调节蛋白相关,参与细胞信息传导、细胞骨架重排的调控,是细胞增殖、分化和运动的重要因素。目前认为,c-met与多种癌的发生和转移密切相关,研究表明,许多肿瘤病人...
1. Huang C, et al. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations. Curr Treat Options Oncol. 2020;21(4): 33. 2. Awad MM. Impaired c-Met Receptor Degradation Mediated by MET Exon...
[3] Gow CH, Hsieh MS, Wu SG, et al. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population[J...
[8] Socinski MA, Pennell NA, Davies KD. MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. JCO Precis Oncol. 2021 Apr 13;5:PO.20.00516. [9] Liu SY, Gou LY, Li AN et al. The unique characteristics of...
[2]. Subramanian J, Tawfik O. Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective. Expert Rev Anticancer Ther. 2021 Aug;21(8):877-886. [3]. MET 14外显子跳跃突变NSCLC靶向治疗专家共识. ...
本例晚期 NSCLC 患者基因检测发现 MET ex14 跳突,接受赛沃替尼一线治疗获得了持久的生存获益,且患者治疗期间未出现严重不良反应。至最后一次随访时,PFS 超 17 个月,至今患者病情稳定,仍在持续获益中。该病例充分验证了赛沃替尼一线治疗 MET ex14 跳突 NSCLC 的良好疗效和可耐受的安全性。此外,该病例还提示,在...
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev 2020; 87: 102022. 7. Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer...
会议摘要:Antitumor effects of ensartinib in non-small cell lung cancer harboring MET exon 14-skipping mutations (摘要编号:4131/15 ;药物:恩沙替尼),即恩沙替尼在MET 14外显子跳跃突变非小细胞肺癌中的抗肿瘤作用。 临床研究探索了新型多激酶抑制剂“恩沙替尼”,对MET外显子14跳跃突变的非小细胞肺癌(NS...
[5]Lu S, Fang J, Li X, et al. 2MO Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC[J]. Annals of Oncology, 2022, 33(S2): S27. *此文仅用于向医学人士提供科学信息,不代表本平台观点...